Next Article in Journal
Elastic Properties and Stability of Physisorbed Graphene
Previous Article in Journal
Electromagnetic Properties of Graphene-like Films in Ka-Band
Previous Article in Special Issue
Radiosynthesis and in Vivo Evaluation of Two PET Radioligands for Imaging α-Synuclein
Article Menu

Export Article

Open AccessArticle
Appl. Sci. 2014, 4(2), 265-281; doi:10.3390/app4020265

CERN-MEDICIS (Medical Isotopes Collected from ISOLDE): A New Facility

CERN, 23 Geneva, 1211-Geneva, Switzerland
Universitaires de Genève (HUG), Rue Gabrielle-Perret-Gentil 4, 1205-Geneva, Switzerland
Author to whom correspondence should be addressed.
Received: 10 November 2013 / Revised: 27 January 2014 / Accepted: 25 February 2014 / Published: 16 May 2014
(This article belongs to the Special Issue Radioisotope Production and Applications)
View Full-Text   |   Download PDF [4706 KB, uploaded 19 May 2014]   |  


About 50% of the 1.4 GeV CERN (European Organization for Nuclear Research, protons are sent onto targets to produce radioactive beams by online mass separation at the Isotope Separator Online Device (ISOLDE) facility, for a wide range of studies in fundamental and applied physics. CERN-MEDICIS is a spin-off dedicated to R&D in life sciences and medical applications. It is located in an extension of the Class A building presently under construction. It will comprise laboratories to receive the irradiated targets from a new station located at the dump position behind the ISOLDE production targets. An increasing range of innovative isotopes will thus progressively become accessible from the start-up of the facility in 2015 onward; for fundamental studies in cancer research, for new imaging and therapy protocols in cell and animal models and for pre-clinical trials, possibly extended to specific early phase clinical studies up to Phase I trials. Five hundred megabecquerel isotope batches purified by electromagnetic mass separation combined with chemical methods will be collected on a weekly basis. A possible future upgrade with gigabecquerel pharmaceutical-grade i.e., current good manufacturing practices (cGMP) batch production capabilities is finally presented. View Full-Text
Keywords: CERN-MEDICIS; ISOLDE; CERN; radioisotope; radiolanthanides; bioconjugates; targeted radiotherapy; targeted alpha therapy (TAT); cancer; PET imaging; theranostics CERN-MEDICIS; ISOLDE; CERN; radioisotope; radiolanthanides; bioconjugates; targeted radiotherapy; targeted alpha therapy (TAT); cancer; PET imaging; theranostics

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

dos Santos Augusto, R.M.; Buehler, L.; Lawson, Z.; Marzari, S.; Stachura, M.; Stora, T.; CERN-MEDICIS collaboration. CERN-MEDICIS (Medical Isotopes Collected from ISOLDE): A New Facility. Appl. Sci. 2014, 4, 265-281.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Appl. Sci. EISSN 2076-3417 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top